INTS Intensity Therapeutics, Inc. restarts patient treatment in the randomized, presurgical triple negative breast cancer phase 2 clinical t

INTS Intensity Therapeutics, Inc. restarts patient treatment in the randomized, presurgical triple negative breast cancer phase 2 clinical trial (invincible-4 study)